Developing Novel Therapeutics for Metabolic and Gastrointestinal Disease
Vogenx is a clinical stage biopharmaceutical company focused on the discovery and development of novel therapies for the treatment of important diseases associated with dysfunctions in human metabolism including post bariatric hypoglycemia and gastroparesis.
Human metabolism is a complex process that involves many biochemicals, tissues, and organs throughout the body and refers to the ongoing biochemical processes that maintain the normal functioning of all living organisms.
The Company’s lead compound, mizagliflozin, is an orally administered, small molecule drug candidate and inhibitor of SGLT1. Mizagliflozin reduces and delays postprandial glucose absorption and reduces secretion of insulin and gastric inhibitory peptide (GIP).
Post bariatric surgery patients, with and without PBH, experience pronounced increases in postprandial blood glucose and insulin compared control.
Blue line: Control (healthy subjects); Green line: Asymptomatic-RYGB (Patients that have had RYGB bariatric surgery but do not have PBH; Red line: PBH-RYGB (Patients that have had RYGB bariatric surgery and have been diagnosed with PBH).
Reference: Salehi M, Gastaldelli A, D’alessio DA. Altered islet function and insulin clearance cause hyperinsulinemia in gastric bypass patients with symptoms of postprandial hypoglycemia. The Journal of Clinical Endocrinology & Metabolism. 2014 Jun; 99(6):
2008-17.
Transforming lives of Patients with rare Disease
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
- Lorem ipsum dolor sit amet
- Consectetur adipiscing elit
- Ut enim ad minim veniam
- Excepteur sint occaecat cupidatat
- Quis nostrud exercitation ullamco
Developing Novel Therapeutics for Metabolic and Gastrointestinal Disease
Vogenx is a clinical stage life science and drug development company focused on the development of novel therapeutics for the treatment of important diseases associated with dysfunctions in human metabolism including post bariatric hypoglycemia (PBH), gastroparesis, and obesity.
Human metabolism is a complex process that involves many biochemicals, tissues, and organs throughout the body and refers to the ongoing biochemical processes that maintain the normal functioning of all living organisms.
The Company’s lead compound is a first-in-class, oral, small molecule drug candidate that inhibits postprandial glucose absorption and reduces secretion of insulin and gastric inhibitory peptide (GIP).